We came across a bullish thesis on Harrow, Inc. on 1035 Capital Management’s Substack. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.’s share was trading at $34.37 as of July 15th. HROW’s trailing P/E was 9.64 according to Yahoo Finance.
A biopharmaceutical laboratory with scientists in lab coats working on medicines.
Harrow (HROW) is executing a focused pharmaceutical rollup strategy within ophthalmology, targeting branded drugs with limited competition...
